Idiopathic	O
ventricular	O
fibrillation	O
occurs	O
with	O
a	O
reputed	O
incidence	O
of	O
approximately	O
1	O
%	O
of	O
all	O
cases	O
of	O
out-of-hospital	O
arrest	O
,	O
as	O
well	O
as	O
3–9	O
%	O
of	O
the	O
cases	O
of	O
ventricular	O
fibrillation	O
unrelated	O
to	O
myocardial	O
infarction	O
,	O
and	O
14	O
%	O
of	O
all	O
ventricular	other-medical
fibrillation	other-medical
resuscitations	other-medical
in	O
patients	O
under	O
the	O
age	O
of	O
40	O
.	O

Niimi	O
received	O
an	O
injection	O
of	O
atropine	other-medical
and	O
pralidoxime	other-medical
iodine	other-medical
,	O
saving	O
his	O
life	O
.	O

In	O
the	O
test	O
for	O
anti-inflammatory	O
activity	O
the	O
extract	O
exhibited	O
17.6	O
%	O
inhibition	O
at	O
a	O
concentration	O
25	O
mg/ml	O
,	O
Ibuprofen	other-medical
being	O
used	O
as	O
a	O
standard	O
drug	O
for	O
comparison	O
and	O
showing	O
73.2	O
%	O
inhibition	O
at	O
the	O
same	O
concentration	O
.	O

According	O
to	O
the	O
CDC	O
,	O
tighter	O
prescription	O
policies	O
by	O
doctors	O
did	O
not	O
necessarily	O
lead	O
to	O
this	O
increased	O
heroin	other-medical
use	O
.	O

In	O
2010	O
,	O
Schulten	O
's	O
group	O
at	O
Illinois	O
and	O
researchers	O
at	O
the	O
University	O
of	O
Utah	O
published	O
research	O
examining	O
the	O
development	O
of	O
drug	O
resistance	O
to	O
Tamiflu	other-medical
in	O
H1N1pdm	O
swine	O
influenza	O
and	O
H5N1	O
avian	O
influenza	O
virus	O
.	O

In	O
the	O
first	O
trial	O
,	O
42	O
%	O
of	O
subjects	O
in	O
the	O
fluoxetine	other-medical
-treated	O
arm	O
were	O
free	O
of	O
panic	O
attacks	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
vs.	O
28	O
%	O
in	O
the	O
placebo	other-medical
arm	O
.	O

Another	O
type	O
of	O
immunotherapy	O
involves	O
vaccines	O
,	O
including	O
TroVax	other-medical
.	O

Various	O
agents	O
can	O
inhibit	O
5-HT	O
reuptake	O
,	O
including	O
cocaine	other-medical
,	O
dextromethorphan	other-medical
(	O
an	O
antitussive	other-medical
)	O
,	O
tricyclic	other-medical
antidepressants	other-medical
and	O
selective	other-medical
serotonin	other-medical
reuptake	other-medical
inhibitors	other-medical
(	O
SSRIs	other-medical
)	O
.	O

Methyltestosterone	O
,	O
one	O
of	O
the	O
first	O
synthetic	O
AAS	other-medical
and	O
orally	O
active	O
androgens	O
,	O
was	O
introduced	O
in	O
1935	O
,	O
but	O
was	O
associated	O
with	O
hepatotoxicity	O
and	O
eventually	O
became	O
largely	O
medically	O
obsolete	O
.	O

Thiopental	other-medical
is	O
famously	O
associated	O
with	O
a	O
number	O
of	O
anesthetic	O
deaths	O
in	O
victims	O
of	O
the	O
attack	O
on	O
Pearl	O
Harbor	O
.	O

Chemotherapy	other-medical
is	O
the	O
initial	O
treatment	O
of	O
choice	O
,	O
and	O
most	O
people	O
with	O
ALL	O
receive	O
a	O
combination	O
of	O
medications	O
.	O

Long-term	other-medical
chronic	other-medical
dialysis	other-medical
,	O
however	O
,	O
the	O
highest	O
standards	O
should	O
be	O
applied	O
to	O
these	O
children	O
to	O
preserve	O
their	O
future	O
``	O
cardiovascular	O
life	O
''	O
—which	O
might	O
include	O
more	O
dialysis	other-medical
time	O
and	O
on-line	O
hemodiafiltration	O
online	O
hdf	O
with	O
synthetic	O
high	O
flux	O
membranes	O
with	O
the	O
surface	O
area	O
of	O
0.2sq.m	O
to	O
0.8sq.m	O
and	O
blood	O
tubing	O
lines	O
with	O
the	O
low	O
volume	O
yet	O
large	O
blood	O
pump	O
segment	O
of	O
6.4/8.0mm	O
,	O
if	O
we	O
are	O
able	O
to	O
improve	O
on	O
the	O
rather	O
restricted	O
concept	O
of	O
small-solute	other-medical
urea	other-medical
dialysis	other-medical
clearance	O
.	O

Tyrosine	other-medical
kinase	other-medical
inhibitors	other-medical
(	O
such	O
as	O
sunitinib	other-medical
,	O
pazopanib	other-medical
,	O
and	O
dasatinib	other-medical
)	O
have	O
shown	O
some	O
effect	O
against	O
several	O
cancer	O
types	O
,	O
most	O
notably	O
Imatinib-mesylate	other-medical
in	O
gastrointestinal	other-medical
stromal	other-medical
tumors	other-medical
(	O
GISTs	other-medical
)	O
.	O

However	O
,	O
this	O
can	O
lead	O
to	O
fat	other-medical
deficiency	other-medical
and	O
malnutrition	other-medical
over	O
time	O
.	O

Complement	other-medical
dysfunction	other-medical
may	O
predispose	O
some	O
patients	O
to	O
bacterial	other-medical
infections	other-medical
.	O

Dr	O
.	O
Lee	O
Suy	O
also	O
added	O
that	O
the	O
stocked	O
1.5	O
million	O
anti-viral	O
medicines	O
such	O
as	O
Tamiflu	other-medical
by	O
the	O
DOH	O
is	O
not	O
enough	O
for	O
possible	O
epidemic	O
since	O
most	O
of	O
them	O
are	O
given	O
free	O
to	O
discourage	O
uncontrolled	O
and	O
panic	O
buying	O
.	O

The	O
main	O
competitors	O
to	O
rosuvastatin	other-medical
are	O
atorvastatin	other-medical
and	O
simvastatin	other-medical
.	O

The	O
FDA	O
has	O
warned	O
that	O
Prozac	other-medical
and	O
similar	O
antidepressants	O
could	O
cause	O
agitation	O
,	O
panic	O
attacks	O
and	O
aggression	O
.	O

Segal	O
suggested	O
an	O
HIV	O
therapy	O
of	O
anti-inflammatory	O
aspirin	other-medical
or	O
ultraviolet	other-medical
radiation	other-medical
of	O
the	O
patient	O
's	O
blood	O
in	O
order	O
to	O
reduce	O
the	O
metabolic	O
activity	O
of	O
macrophages	O
,	O
which	O
are	O
host	O
cells	O
for	O
HIV	O
.	O

As	O
such	O
,	O
as	O
tramadol	other-medical
is	O
related	O
to	O
venlafaxine	other-medical
,	O
the	O
same	O
conditions	O
apply	O
.	O

The	O
residual	O
fungus	O
is	O
treated	O
with	O
topical	O
antifungals	O
,	O
usually	O
either	O
1	O
%	O
tolnaftate	other-medical
(	O
Tinactin	other-medical
)	O
or	O
1	O
%	O
chlortrimazole	other-medical
(	O
Lotrimin	other-medical
)	O
solution	O
,	O
10	O
drops	O
twice	O
a	O
day	O
for	O
3	O
days	O
.	O

Disseminated	O
intravascular	other-medical
coagulation	other-medical
occurs	O
as	O
the	O
toxin	O
interacts	O
with	O
the	O
victim	O
's	O
body	O
.	O

The	O
difference	O
between	O
the	O
vardenafil	other-medical
molecule	other-medical
and	O
sildenafil	other-medical
citrate	other-medical
is	O
a	O
nitrogen	O
atom	O
's	O
position	O
and	O
the	O
change	O
of	O
sildenafil	other-medical
's	O
piperazine	other-medical
ring	other-medical
methyl	other-medical
group	other-medical
to	O
an	O
ethyl	other-medical
group	other-medical
.	O

The	O
most	O
common	O
adverse	O
effects	O
include	O
:	O
hepatotoxicity	O
(	O
liver	O
damage	O
)	O
,	O
ulcerative	O
stomatitis	O
,	O
leukopenia	O
and	O
thus	O
predisposition	O
to	O
infection	other-medical
,	O
nausea	other-medical
,	O
abdominal	other-medical
pain	other-medical
,	O
fatigue	other-medical
,	O
fever	other-medical
,	O
dizziness	other-medical
,	O
acute	O
pneumonitis	O
,	O
rarely	O
pulmonary	O
fibrosis	O
,	O
and	O
kidney	other-medical
failure	other-medical
.	O

Furosemide	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Lasix	O
among	O
others	O
,	O
is	O
a	O
loop	O
diuretic	O
medication	O
used	O
to	O
treat	O
fluid	O
build-up	O
due	O
to	O
heart	O
failure	O
,	O
liver	O
scarring	O
,	O
or	O
kidney	O
disease	O
.	O

While	O
many	O
statin	O
medications	O
should	O
be	O
administered	O
at	O
bedtime	O
for	O
optimal	O
effect	O
,	O
atorvastatin	other-medical
can	O
be	O
dosed	O
at	O
any	O
time	O
of	O
day	O
,	O
as	O
long	O
as	O
it	O
is	O
continually	O
dosed	O
once	O
daily	O
at	O
the	O
same	O
time	O
.	O

Chronic	O
use	O
of	O
benzodiazepines	other-medical
can	O
lead	O
to	O
the	O
development	O
of	O
tolerance	O
with	O
a	O
decrease	O
of	O
benzodiazepine	other-medical
binding	O
sites	O
.	O

Gene	other-medical
therapy	other-medical
in	other-medical
SMA	other-medical
aims	O
at	O
restoring	O
the	O
``	O
SMN1	O
``	O
gene	O
function	O
through	O
inserting	O
specially	O
crafted	O
nucleotide	O
sequence	O
(	O
a	O
``	O
SMN1	O
``	O
transgene	O
)	O
into	O
the	O
cell	O
nucleus	O
using	O
a	O
viral	O
vector	O
;	O
scAAV-9	O
and	O
scAAV-10	O
are	O
the	O
primary	O
viral	O
vectors	O
under	O
investigation	O
.	O

25B-NBOH	other-medical
(	O
2C-B-NBOH	other-medical
,	O
NBOH-2C-B	other-medical
)	O
is	O
a	O
derivative	O
of	O
the	O
phenethylamine	O
derived	O
hallucinogen	other-medical
2C-B	other-medical
which	O
has	O
been	O
sold	O
as	O
a	O
designer	O
drug	O
.	O

One	O
study	O
found	O
approximately	O
15	O
%	O
of	O
chronic	O
MDMA	O
users	O
met	O
the	O
DSM-IV	other-medical
diagnostic	O
criteria	O
for	O
substance	O
dependence	O
.	O

Cannabicyclohexanol	other-medical
is	O
not	O
listed	O
in	O
the	O
schedules	O
set	O
out	O
by	O
the	O
United	O
Nations	O
'	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
from	O
1961	O
nor	O
their	O
Convention	O
on	O
Psychotropic	O
Substances	O
from	O
1971	O
,	O
so	O
the	O
signatory	O
countries	O
to	O
these	O
international	O
drug	O
control	O
treaties	O
are	O
not	O
required	O
by	O
said	O
treaties	O
to	O
control	O
Cannabicyclohexanol	other-medical
.	O

Antifungal	O
drugs	O
including	O
ketoconazole	other-medical
,	O
miconazole	other-medical
,	O
5-flucytosine	other-medical
and	O
pentamidine	other-medical
have	O
been	O
shown	O
to	O
be	O
effective	O
against	O
``	O
Acanthamoeba	O
``	O
``	O
in	O
vitro	O
''	O
.	O

In	O
2019	O
an	O
AAV9	other-medical
therapy	other-medical
was	O
approved	O
:	O
Onasemnogene	other-medical
abeparvovec	other-medical
.	O

A	O
few	O
studies	O
have	O
examined	O
the	O
impact	O
of	O
haloperidol	other-medical
exposure	O
on	O
breastfed	O
infants	O
and	O
in	O
most	O
cases	O
,	O
there	O
were	O
no	O
adverse	O
effects	O
on	O
infant	O
growth	O
and	O
development	O
.	O

Court	O
acknowledged	O
that	O
physical	O
efficacy	O
of	O
imatinib	other-medical
mesylate	O
in	O
beta	O
crystalline	O
form	O
is	O
enhanced	O
in	O
comparison	O
to	O
other	O
forms	O
and	O
that	O
the	O
beta	O
crystalline	O
form	O
of	O
imatinib	other-medical
mesylate	O
has	O
30	O
per	O
cent	O
increased	O
bioavailability	O
as	O
compared	O
to	O
imatinib	other-medical
in	O
free	O
base	O
form	O
.	O

On	O
January	O
25	O
,	O
2011	O
,	O
the	O
FDA	O
approved	O
over-the-counter	O
sales	O
of	O
fexofenadine	other-medical
in	O
the	O
United	O
States	O
,	O
and	O
Sanofi	O
Aventis	O
'	O
version	O
became	O
available	O
on	O
March	O
4	O
,	O
2011	O
.	O

The	O
first	O
half	O
of	O
the	O
1960	O
’	O
s	O
saw	O
contraceptions	O
such	O
as	O
the	O
birth	other-medical
control	other-medical
pill	other-medical
and	O
Intrauterine	other-medical
Device	other-medical
(	O
IUD	other-medical
)	O
become	O
widely	O
available	O
,	O
which	O
contributed	O
to	O
sexual	O
freedom	O
for	O
many	O
people	O
without	O
having	O
to	O
rely	O
on	O
less	O
reliable	O
and	O
uncomfortable	O
physical	O
contraceptives	O
such	O
as	O
condoms	other-medical
or	O
diaphragms	other-medical
.	O

People	O
taking	O
lithium	other-medical
thus	O
should	O
routinely	O
be	O
assessed	O
for	O
hypothyroidism	O
and	O
treated	O
with	O
synthetic	other-medical
thyroxine	other-medical
if	O
necessary	O
.	O

Gemzar	other-medical
also	O
is	O
routinely	O
used	O
in	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Mescaline	other-medical
is	O
biosynthesized	O
from	O
tyrosine	O
which	O
,	O
in	O
turn	O
,	O
is	O
derived	O
from	O
phenylalanine	O
by	O
the	O
enzyme	O
phenylalanine	O
hydroxylase	O
.	O

A	O
possible	O
response	O
to	O
this	O
drawback	O
is	O
a	O
venous	other-medical
fat	other-medical
hemorrhage	other-medical
,	O
in	O
which	O
small	O
and	O
medium-chain	O
fatty	O
acids	O
are	O
given	O
by	O
diet	O
,	O
and	O
long-chain	O
fatty	O
acids	O
are	O
given	O
intravenously	O
.	O

Approximately	O
5	O
%	O
of	O
the	O
patients	O
who	O
have	O
taken	O
hydralazine	other-medical
over	O
long	O
periods	O
of	O
time	O
and	O
in	O
high	O
doses	O
have	O
shown	O
DIL	O
-like	O
symptoms	O
.	O

However	O
,	O
individuals	O
with	O
X-linked	O
thrombocytopenia	O
have	O
an	O
increased	O
risk	O
for	O
life-threatening	O
brain	other-medical
hemorrhages	other-medical
and	O
spontaneous	other-medical
bleeding	other-medical
.	O

There	O
is	O
wide	O
variation	O
in	O
the	O
professional	O
practice	O
of	O
behavior	O
analysis	O
and	O
among	O
the	O
assessments	O
and	O
interventions	O
used	O
in	O
school-based	O
ABA	other-medical
programs	O
.	O

Methylene	other-medical
blue	other-medical
is	O
also	O
used	O
as	O
a	O
dye	O
in	O
chromoendoscopy	O
,	O
and	O
is	O
sprayed	O
onto	O
the	O
mucosa	O
of	O
the	O
gastrointestinal	O
tract	O
in	O
order	O
to	O
identify	O
dysplasia	O
,	O
or	O
pre-cancerous	O
lesions	O
.	O

The	O
anesthetic	O
and	O
intoxicating	O
effects	O
of	O
ether	other-medical
have	O
made	O
it	O
a	O
recreational	O
drug	O
.	O

RTI-120	O
has	O
a	O
short	O
duration	O
of	O
action	O
,	O
along	O
with	O
other	O
p-	O
methyl	O
substituted	O
phenyltropanes	O
such	O
as	O
RTI-150	O
,	O
RTI-171	O
and	O
RTI-199	O
,	O
giving	O
it	O
a	O
more	O
similar	O
pharmacological	O
profile	O
to	O
cocaine	other-medical
compared	O
to	O
longer	O
acting	O
analogues	O
like	O
RTI-121	O
and	O
RTI-177	O
.	O

In	O
breast	O
tissue	O
,	O
tamoxifen	other-medical
acts	O
as	O
an	O
ER	O
antagonist	O
so	O
that	O
transcription	O
of	O
estrogen-responsive	O
genes	O
is	O
inhibited	O
.	O

Erythromelalgia	O
is	O
caused	O
by	O
an	O
increased	O
platelet	O
count	O
or	O
increased	O
platelet	O
``	O
stickiness	O
''	O
(	O
aggregation	O
)	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
tiny	O
blood	O
clots	O
in	O
the	O
vessels	O
of	O
the	O
extremity	O
;	O
it	O
responds	O
rapidly	O
to	O
treatment	O
with	O
aspirin	other-medical
.	O

However	O
,	O
people	O
can	O
also	O
combine	O
ezetimibe	other-medical
with	O
either	O
simvastatin	other-medical
or	O
atorvastatin	other-medical
and	O
other	O
agents	O
on	O
their	O
own	O
,	O
for	O
somewhat	O
similar	O
augmented	O
response	O
rates	O
.	O

Israel	O
has	O
the	O
highest	O
rate	O
of	O
IVF	other-medical
in	O
the	O
world	O
,	O
with	O
1657	O
procedures	O
performed	O
per	O
million	O
people	O
per	O
year	O
.	O

He	O
announced	O
the	O
importance	O
of	O
the	O
work	O
of	O
two	O
Bristol	O
colleagues	O
,	O
Frederick	O
Brittan	O
and	O
Joseph	O
Griffiths	O
Swayne	O
,	O
of	O
organisms	O
(	O
described	O
as	O
``	O
fungoid	O
``	O
)	O
in	O
the	O
``	O
rice-water	other-medical
evacuations	other-medical
``	O
of	O
cholera	O
victims	O
.	O

Like	O
primaquine	other-medical
,	O
pamaquine	other-medical
causes	O
haemolytic	O
anaemia	O
in	O
patients	O
with	O
G6PD	O
deficiency	O
.	O

Doxepin	other-medical
is	O
a	O
tertiary	O
amine	O
TCA	other-medical
,	O
with	O
its	O
side	O
chain-demethylated	O
metabolite	O
nordoxepin	O
being	O
a	O
secondary	O
amine	O
.	O

Menopause	O
can	O
be	O
surgically	O
induced	O
by	O
bilateral	other-medical
oophorectomy	other-medical
(	O
removal	O
of	O
ovaries	O
)	O
,	O
which	O
is	O
often	O
,	O
but	O
not	O
always	O
,	O
done	O
in	O
conjunction	O
with	O
removal	O
of	O
the	O
Fallopian	other-medical
tubes	other-medical
(	O
salpingo-oophorectomy	O
)	O
and	O
uterus	other-medical
(	O
hysterectomy	O
)	O
.	O

Mary	O
Edison	O
died	O
at	O
age	O
29	O
on	O
August	O
9	O
,	O
1884	O
,	O
of	O
unknown	O
causes	O
:	O
possibly	O
from	O
a	O
brain	O
tumor	O
or	O
a	O
morphine	other-medical
overdose	O
.	O

Cardiac	other-medical
arrest	other-medical
can	O
also	O
occur	O
after	O
a	O
hard	O
blow	O
to	O
the	O
chest	O
at	O
a	O
precise	O
moment	O
in	O
the	O
cardiac	O
cycle	O
,	O
which	O
is	O
known	O
as	O
commotio	other-medical
cordis	other-medical
.	O

Physicians	O
have	O
called	O
for	O
more	O
research	O
to	O
better	O
understand	O
the	O
potential	O
benefits	O
of	O
controlled	O
use	O
of	O
medical	other-medical
marijuana	other-medical
;	O
Sharon	O
Levy	O
,	O
director	O
of	O
the	O
Adolescent	O
Substance	O
Abuse	O
Program	O
at	O
Children	O
's	O
Hospital	O
Boston	O
said	O
:	O

The	O
Demon	O
Under	O
the	O
Microscope	O
:	O
From	O
Battlefield	O
Hospitals	O
to	O
Nazi	O
Labs	O
,	O
One	O
Doctor	O
's	O
Heroic	O
Search	O
for	O
the	O
World	O
's	O
First	O
Miracle	O
Drug	O
is	O
a	O
2006	O
nonfiction	O
book	O
about	O
the	O
discovery	O
of	O
Prontosil	other-medical
,	O
the	O
first	O
commercially	O
available	O
antibacterial	other-medical
antibiotic	other-medical
and	O
sulfanilamide	other-medical
,	O
the	O
second	O
commercial	O
antibiotic	other-medical
.	O

Melatonin	other-medical
receptor	other-medical
agonists	other-medical
are	O
analogues	O
of	O
melatonin	O
that	O
bind	O
to	O
and	O
activate	O
the	O
melatonin	O
receptor	O
.	O

Vardenafil	other-medical
's	O
relatively	O
short	O
effective	O
time	O
is	O
comparable	O
to	O
but	O
somewhat	O
longer	O
than	O
sildenafil	other-medical
's	O
.	O

URL	O
Pharma	O
raised	O
the	O
price	O
from	O
$	O
0.09	O
per	O
tablet	O
to	O
$	O
4.85	O
,	O
and	O
the	O
FDA	O
removed	O
the	O
older	O
unapproved	O
colchicine	other-medical
from	O
the	O
market	O
in	O
October	O
2010	O
,	O
both	O
in	O
oral	O
and	O
intravenous	O
forms	O
,	O
but	O
gave	O
pharmacies	O
the	O
opportunity	O
to	O
buy	O
up	O
the	O
older	O
unapproved	O
colchicine	other-medical
.	O

Sinus	O
node	O
blocker	O
Ivabradine	other-medical
can	O
successfully	O
restrain	O
heart	O
rate	O
in	O
POTS	O
without	O
affecting	O
blood	O
pressure	O
,	O
demonstrated	O
in	O
approximately	O
60	O
%	O
of	O
people	O
with	O
POTS	O
treated	O
in	O
an	O
open-label	O
trial	O
of	O
ivabradine	other-medical
experienced	O
symptom	O
improvement	O
.	O

Lamivudine	other-medical
is	O
often	O
given	O
in	O
combination	O
with	O
zidovudine	other-medical
,	O
with	O
which	O
it	O
is	O
highly	O
synergistic	O
.	O

5-ARIs	other-medical
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
hirsutism	O
in	O
women	O
.	O

Insulin	O
regulates	O
blood	O
glucose	O
levels	O
while	O
CCK	O
adjusts	O
gastric	other-medical
emptying	other-medical
,	O
pancreatic	other-medical
secretion	other-medical
and	O
gall	other-medical
bladder	other-medical
contraction	other-medical
.	O

Blocking	O
CCR5	O
with	O
Maraviroc	other-medical
(	O
a	O
drug	O
approved	O
for	O
HIV	O
)	O
may	O
enhance	O
recovery	O
after	O
stroke	O
.	O

P28GST	other-medical
is	O
thus	O
a	O
promising	O
potential	O
therapeutic	O
for	O
treating	O
inflammatory	O
bowel	O
diseases	O
like	O
Crohn	O
’	O
s	O
disease	O
and	O
ulcerative	O
colitis	O
.	O

Other	O
brand	O
names	O
of	O
MPA	other-medical
formulated	O
alone	O
include	O
Farlutal	other-medical
and	O
Sayana	other-medical
for	O
clinical	O
use	O
and	O
Depo-Promone	other-medical
,	O
Perlutex	other-medical
,	O
Promone-E	other-medical
,	O
and	O
Veramix	other-medical
for	O
veterinary	O
use	O
.	O

The	O
sPLA2	O
inhibitor	O
,	O
LY315920	other-medical
(	O
varespladib	other-medical
sodium	other-medical
)	O
,	O
and	O
its	O
orally	other-medical
bioavailable	other-medical
prodrug	other-medical
,	O
LY333013	other-medical
(	O
varespladib	other-medical
methyl	other-medical
)	O
were	O
highly	O
effective	O
in	O
preventing	O
lethality	O
following	O
experimental	O
envenoming	O
by	O
M.	O
fulvius	O
in	O
a	O
porcine	O
animal	O
model	O
.	O

NIDA	O
has	O
drawn	O
criticism	O
for	O
continuing	O
to	O
provide	O
funding	O
to	O
George	O
Ricaurte	O
,	O
who	O
in	O
2002	O
conducted	O
a	O
study	O
that	O
was	O
widely	O
touted	O
as	O
proving	O
that	O
MDMA	other-medical
(	O
ecstasy	O
)	O
caused	O
dopaminergic	O
neurotoxicity	O
in	O
monkeys	O
.	O

In	O
insulin-dependent	O
diabetic	O
people	O
,	O
this	O
phenomenon	O
is	O
termed	O
hypoglycemia	other-medical
unawareness	O
,	O
and	O
is	O
a	O
significant	O
clinical	O
problem	O
when	O
improved	O
glycemic	O
control	O
is	O
attempted	O
.	O

Transurethral	other-medical
injection	other-medical
of	O
bulking	O
agents	O
have	O
little	O
role	O
in	O
the	O
management	O
of	O
post-prostatecromy	O
incontinence	O
and	O
there	O
is	O
weak	O
evidence	O
that	O
these	O
agents	O
can	O
offer	O
any	O
improvement	O
.	O

This	O
has	O
led	O
to	O
carboplatin	other-medical
based	O
adjuvant	O
therapy	O
being	O
generally	O
preferred	O
over	O
adjuvant	O
radiotherapy	O
in	O
clinical	O
practice	O
.	O

``	O
NSAIDs	other-medical
``	O
,	O
or	O
non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
may	O
help	O
improve	O
the	O
lameness	O
in	O
the	O
horse	O
.	O

If	O
the	O
person	O
presents	O
symptoms	O
of	O
hyperthyroidism	other-medical
,	O
doctors	O
are	O
more	O
likely	O
to	O
test	O
for	O
Thyroid	O
stimulating	O
hormone	O
receptor	O
Antibodies	O
(	O
TRAb	O
)	O
,	O
and	O
monitor	O
the	O
effects	O
of	O
anti-thyroid	other-medical
therapy	O
,	O
also	O
associated	O
with	O
Graves	O
'	O
disease	O
.	O

However	O
,	O
in	O
part	O
due	O
to	O
bad	O
publicity	O
from	O
its	O
illicit	O
use	O
by	O
bodybuilders	O
,	O
production	O
of	O
Anavar	other-medical
was	O
discontinued	O
by	O
Searle	O
Laboratories	O
in	O
1989	O
.	O

The	O
KRAS	O
gene	O
encodes	O
a	O
small	O
G	O
protein	O
on	O
the	O
EGFR	other-medical
pathway	O
.	O

For	O
example	O
,	O
if	O
breakfast	O
cereal	O
in	O
Canada	O
is	O
fortified	O
,	O
they	O
must	O
contain	O
the	O
following	O
specific	O
amounts	O
per	O
100	O
grams	O
of	O
cereal	O
:	O
Thiamine	O
(	O
2.0	O
mg	O
)	O
,	O
Niacin	O
(	O
4.8	O
mg	O
)	O
,	O
Vitamin	other-medical
B6	other-medical
(	O
0.6	O
mg	O
)	O
,	O
Folic	O
Acid	O
(	O
0.06	O
mg	O
)	O
,	O
Pantothenic	O
Acid	O
(	O
1.6	O
mg	O
)	O
,	O
Magnesium	O
(	O
160.0	O
mg	O
)	O
,	O
Iron	O
(	O
13.3	O
mg	O
)	O
,	O
Zinc	O
(	O
3.5	O
mg	O
)	O
.	O

These	O
children	O
had	O
respiratory	O
tract	O
infections	O
at	O
the	O
time	O
the	O
specimens	O
were	O
collected	O
(	O
in	O
one	O
girl	O
so	O
severe	O
that	O
mechanical	other-medical
ventilation	other-medical
was	O
needed	O
)	O
,	O
while	O
testing	O
negative	O
for	O
other	O
causes	O
like	O
Human	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
,	O
parainfluenza	O
virus	O
es	O
(	O
types	O
1–3	O
)	O
,	O
influenza	O
A	O
and	O
B	O
viruses	O
,	O
and	O
adenovirus	O
by	O
direct	O
immunofluorescence	O
assay	O
as	O
well	O
as	O
human	O
metapneumovirus	O
and	O
HCoV-NH	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

Pyrovalerone	other-medical
(	O
Centroton	other-medical
,	O
4-Methyl-β-keto-prolintane	other-medical
,	O
Thymergix	other-medical
,	O
O-2371	other-medical
)	O
is	O
a	O
psychoactive	O
drug	O
with	O
stimulant	O
effects	O
via	O
acting	O
as	O
a	O
norepinephrine-dopamine	other-medical
reuptake	other-medical
inhibitor	other-medical
(	O
NDRI	other-medical
)	O
,	O
and	O
is	O
used	O
for	O
the	O
clinical	O
treatment	O
of	O
chronic	O
fatigue	O
or	O
lethargy	O
and	O
as	O
an	O
anorectic	O
or	O
appetite	O
suppressant	O
for	O
weight	O
loss	O
purposes	O
.	O

After	O
24	O
hours	O
,	O
a	O
severe	O
bleeding	O
disorder	O
ensues	O
,	O
leading	O
to	O
ecchymosis	other-medical
,	O
hematuria	other-medical
,	O
pulmonary	other-medical
,	O
and	O
intracranial	other-medical
hemorrhages	other-medical
,	O
and	O
acute	other-medical
kidney	other-medical
injury	other-medical
.	O

The	O
problem	O
is	O
with	O
paracetamol	other-medical
(	O
acetaminophen	other-medical
/	O
Tylenol	other-medical
for	O
example	O
)	O
overdose	O
and	O
liver	O
damage	O
.	O

Triptans	other-medical
have	O
advantages	O
over	O
ergotamine	other-medical
and	O
dihydroergotamine	other-medical
,	O
such	O
as	O
selective	O
pharmacology	O
,	O
well	O
established	O
safety	O
record	O
and	O
evidence-based	O
prescribing	O
instructions	O
.	O

GSK	O
used	O
the	O
``	O
JAACAP	O
``	O
article	O
to	O
promote	O
paroxetine	other-medical
to	O
doctors	O
for	O
use	O
in	O
their	O
teenage	O
patients	O
.	O

The	O
first	O
hyaluronan	O
biomedical	O
product	O
,	O
Healon	O
,	O
was	O
developed	O
in	O
the	O
1970s	O
and	O
1980s	O
by	O
Pharmacia	O
,	O
and	O
approved	O
for	O
use	O
in	O
eye	O
surgery	O
(	O
i.e.	O
,	O
corneal	other-medical
transplantation	other-medical
,	O
cataract	other-medical
surgery	other-medical
,	O
glaucoma	other-medical
surgery	other-medical
,	O
and	O
surgery	O
to	O
repair	other-medical
retinal	other-medical
detachment	other-medical
)	O
.	O

Adderall	other-medical
is	O
a	O
drug	O
that	O
affects	O
the	O
central	O
nervous	O
system	O
and	O
is	O
prescribed	O
to	O
individuals	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
and/or	O
narcolepsy	O
.	O

Clomethiazole	other-medical
acts	O
as	O
a	O
positive	O
allosteric	O
modulator	O
at	O
the	O
barbiturate	O
/	O
picrotoxin	O
site	O
of	O
the	O
GABAA	O
receptor	O
.	O

But	O
there	O
is	O
also	O
a	O
genetic	O
connection	O
of	O
STPD	O
to	O
mood	other-medical
disorders	other-medical
and	O
depression	O
in	O
particular	O
.	O

The	O
American	O
Dental	O
Association	O
(	O
ADA	O
)	O
recommends	O
antibiotic	other-medical
prophylaxis	other-medical
for	O
very	O
few	O
people	O
since	O
only	O
a	O
small	O
number	O
of	O
cases	O
of	O
endocarditis	O
might	O
be	O
caused	O
by	O
dental	O
procedures	O
.	O

In	O
type	O
3	O
diabetes	O
,	O
the	O
neurons	other-medical
lack	O
glucose	other-medical
,	O
a	O
key	O
element	O
needed	O
for	O
the	O
neurons	other-medical
to	O
function	O
effectively	O
in	O
body	O
however	O
more	O
specifically	O
the	O
hippocampus	other-medical
and	O
the	O
cerebral	other-medical
cortex	other-medical
.	O

The	O
initial	O
discovery	O
of	O
spirorenone	other-medical
was	O
deemed	O
a	O
great	O
success	O
,	O
as	O
no	O
compound	O
with	O
greater	O
antimineralocorticoid	O
activity	O
had	O
been	O
developed	O
since	O
spironolactone	O
in	O
1957	O
.	O

In	O
January	O
1940	O
Seddon	O
was	O
appointed	O
to	O
the	O
Nuffield	other-medical
Chair	other-medical
of	other-medical
Orthopaedic	other-medical
Surgery	other-medical
at	O
the	O
University	O
of	O
Oxford	O
.	O

Vintafolide	other-medical
,	O
which	O
consists	O
of	O
an	O
antifolate	O
conjugated	O
with	O
vinblastine	other-medical
,	O
is	O
also	O
in	O
clinical	O
trials	O
;	O
it	O
may	O
prove	O
beneficial	O
because	O
folate	O
receptors	O
are	O
overexpressed	O
in	O
many	O
ovarian	O
cancers	O
.	O

The	O
chemical	O
name	O
of	O
doxepin	other-medical
is	O
(	O
``	O
E	O
''	O
/	O
''	O
Z	O
''	O
)	O
-3-	O
(	O
dibenzo	O
[	O
``	O
b	O
''	O
,	O
''	O
e	O
''	O
]	O
oxepin-11	O
(	O
6	O
''	O
H	O
''	O
)	O
-ylidene	O
)	O
-	O
''	O
N	O
''	O
,	O
''	O
N	O
''	O
-dimethylpropan-1-amine	O
and	O
its	O
free	O
base	O
form	O
has	O
a	O
chemical	O
formula	O
of	O
C19H21NO	O
with	O
a	O
molecular	O
weight	O
of	O
279.376	O
g/mol	O
.	O

“	O
Mononeuropathy	O
refers	O
to	O
single	O
peripheral	O
nerve	O
involvement	O
and	O
usually	O
occurs	O
due	O
to	O
trauma	other-medical
,	O
compression	other-medical
or	O
entrapment	other-medical
”	O
.	O

This	O
drug	O
is	O
commonly	O
misused	O
by	O
college	O
students	O
as	O
a	O
``	O
study	O
drug	O
,	O
''	O
although	O
research	O
suggests	O
that	O
stimulants	other-medical
are	O
more	O
efficient	O
at	O
correcting	O
shortfalls	O
than	O
enhancing	O
performance	O
.	O

Natalizumab	other-medical
halves	O
the	O
risk	O
of	O
suffering	O
relapses	O
when	O
compared	O
to	O
interferons	O
,	O
having	O
an	O
overall	O
efficacy	O
of	O
over	O
70	O
%	O
.	O

In	O
addition	O
he	O
became	O
a	O
professorial	O
fellow	O
of	O
Worcester	O
College	O
,	O
Oxford	O
and	O
for	O
clinical	O
duties	O
he	O
became	O
clinical	O
director	O
at	O
the	O
Wingfield-Morris	O
Hospital	O
,	O
later	O
renamed	O
the	O
Nuffield	other-medical
Orthopaedic	other-medical
Centre	other-medical
(	O
NOC	other-medical
)	O
and	O
subsequently	O
part	O
of	O
Oxford	O
University	O
Hospitals	O
NHS	O
Trust	O
.	O

The	O
effects	O
of	O
recreational	O
use	O
are	O
exhaustion	O
and	O
an	O
accumulation	O
of	O
“	O
sleep	O
debt.	O
”	O
Furthermore	O
,	O
frequent	O
use	O
of	O
adderall	other-medical
during	O
the	O
day	O
and	O
night	O
can	O
lead	O
to	O
sleep	O
deprivation	O
and	O
insomnia	O
.	O

The	O
result	O
is	O
high	O
glucose	other-medical
levels	O
in	O
the	O
blood	O
which	O
leave	O
the	O
individual	O
feeling	O
tired	O
and	O
weak	O
in	O
most	O
cases	O
.	O

In	O
humans	O
,	O
tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
clonazepam	other-medical
occurs	O
frequently	O
.	O

Acyclovir	other-medical
is	O
a	O
better	O
antiviral	O
because	O
it	O
shows	O
a	O
similar	O
effect	O
on	O
the	O
infection	O
as	O
vidarabine	other-medical
and	O
is	O
safer	O
to	O
use	O
in	O
neonates	O
.	O

Flumazenil	other-medical
effectively	O
blocks	O
the	O
effects	O
of	O
benzodiazepine	other-medical
agonists	O
such	O
as	O
alprazolam	other-medical
and	O
diazepam	other-medical
and	O
so	O
is	O
used	O
for	O
treating	O
overdoses	O
of	O
these	O
drugs	O
but	O
is	O
ineffective	O
in	O
blocking	O
alcohol	O
actions	O
.	O

Carboplatin	other-medical
has	O
also	O
been	O
used	O
for	O
adjuvant	O
therapy	O
of	O
stage	O
1	O
seminomatous	O
testicular	O
cancer	O
.	O

The	O
Mexican	O
traveller	O
was	O
also	O
discharged	O
after	O
treatment	O
with	O
the	O
antiviral	O
drug	O
Tamiflu	other-medical
and	O
the	O
Centre	O
for	O
Health	O
Protection	O
confirmed	O
that	O
he	O
was	O
no	O
longer	O
carrying	O
the	O
virus	O
.	O

Serious	O
cardiac	O
events	O
,	O
including	O
some	O
that	O
have	O
been	O
fatal	O
,	O
have	O
occurred	O
following	O
the	O
use	O
of	O
sumatriptan	other-medical
injection	O
or	O
tablets	O
.	O

This	O
mechanism	O
also	O
explains	O
the	O
selection	O
of	O
HER2/neu	O
(	O
also	O
called	O
ERBB2	O
)	O
and	O
the	O
overexpressing	O
(	O
lineage-addicted	O
)	O
cancer	O
cells	O
during	O
the	O
process	O
of	O
carcinogenesis	O
,	O
and	O
the	O
efficacy	O
of	O
targeted	O
therapy	O
against	O
the	O
Her-2	O
receptor	O
with	O
trastuzumab	other-medical
(	O
Herceptin	other-medical
)	O
in	O
the	O
treatment	O
of	O
adenocarcinomas	O
at	O
the	O
gastroesophageal	O
junction	O
.	O

Allergan	O
,	O
the	O
manufacturer	O
of	O
Botox	other-medical
,	O
agreed	O
to	O
a	O
$	O
600	O
million	O
settlement	O
to	O
resolve	O
all	O
civil	O
and	O
criminal	O
liability	O
surrounding	O
the	O
promotion	O
of	O
Botox	other-medical
for	O
treatment	O
of	O
chronic	O
migraines	O
before	O
FDA	O
review	O
or	O
approval	O
of	O
the	O
drug	O
for	O
such	O
use	O
.	O

Mary	O
Ellen	O
Beck	O
Wohl	O
was	O
chief	O
of	O
the	O
respiratory	other-medical
diseases	O
division	O
at	O
Children	O
's	O
Hospital	O
Boston	O
(	O
a	O
teaching	O
hospital	O
of	O
Harvard	O
Medical	O
School	O
)	O
,	O
and	O
served	O
as	O
associate	O
director	O
of	O
the	O
general	O
clinical	O
research	O
center	O
until	O
a	O
few	O
years	O
before	O
her	O
death	O
in	O
November	O
2009	O
.	O

The	O
anti	O
convulsion	O
drug	O
Lamotrigine	other-medical
has	O
shown	O
some	O
success	O
in	O
treating	O
symptoms	O
of	O
depersonalization	O
,	O
often	O
in	O
combination	O
with	O
a	O
Selective	O
serotonin	O
reuptake	O
inhibitor	O
and	O
is	O
the	O
first	O
drug	O
of	O
choice	O
at	O
the	O
depersonalisation	O
research	O
unit	O
at	O
King	O
's	O
College	O
London	O
.	O

The	O
oral	O
bioavailability	O
of	O
seletracetam	other-medical
is	O
&	O
gt	O
;	O
90	O
%	O
and	O
its	O
half-life	O
is	O
approximately	O
8	O
hours	O
.	O

Rotigotine	other-medical
behaves	O
as	O
a	O
partial	O
or	O
full	O
agonist	O
(	O
depending	O
on	O
the	O
assay	O
)	O
at	O
all	O
dopamine	O
receptors	O
listed	O
,	O
as	O
an	O
antagonist	O
at	O
the	O
α2B-adrenergic	O
receptor	O
,	O
and	O
as	O
a	O
partial	O
agonist	O
at	O
the	O
5-HT1A	O
receptor	O
.	O

Another	O
potential	O
immunotherapy	O
is	O
trastuzumab	other-medical
,	O
which	O
is	O
active	O
against	O
tumors	O
positive	O
for	O
Her2	O
/	O
neu	O
mutations	O
.	O

Note	O
that	O
treatment	O
of	O
a	O
keloid	other-medical
scar	other-medical
is	O
age	O
dependent	O
:	O
radiotherapy	other-medical
,	O
anti-metabolites	other-medical
and	O
corticosteroids	other-medical
would	O
not	O
be	O
recommended	O
to	O
be	O
used	O
in	O
children	O
,	O
in	O
order	O
to	O
avoid	O
harmful	O
side	O
effects	O
,	O
like	O
growth	other-medical
abnormalities	other-medical
.	O

It	O
is	O
also	O
combined	O
with	O
ephedrine	O
to	O
produce	O
Primatene	other-medical
and	O
Bronkaid	other-medical
tablets	O
for	O
symptomatic	O
relief	O
of	O
asthma	O
.	O

Benzodiazepines	other-medical
,	O
including	O
lorazepam	other-medical
,	O
clonazepam	other-medical
and	O
diazepam	other-medical
,	O
are	O
types	O
of	O
anti-anxiety	O
medications	O
.	O

Howson	O
has	O
been	O
debilitated	O
,	O
at	O
times	O
,	O
by	O
Spasmodic	O
Dysphonia	O
which	O
affects	O
his	O
voice	O
;	O
it	O
is	O
periodically	O
mitigated	O
by	O
Botox	other-medical
injections	O
into	O
his	O
larynx	O
.	O

Neuraminidase	other-medical
inhibitors	other-medical
(	O
NAIs	other-medical
)	O
are	O
a	O
class	O
of	O
drugs	O
which	O
block	O
the	O
neuraminidase	O
enzyme	O
.	O

His	O
early	O
work	O
focused	O
on	O
premature	O
ejaculation	O
and	O
erectile	O
dysfunction	O
,	O
and	O
he	O
has	O
written	O
on	O
a	O
number	O
of	O
treatment	O
options	O
,	O
including	O
vacuum	other-medical
pumps	other-medical
,	O
injections	other-medical
into	other-medical
the	other-medical
corpus	other-medical
cavernosum	other-medical
of	other-medical
the	other-medical
penis	other-medical
,	O
and	O
Viagra	other-medical
.	O

Other	O
blood	O
thinners	O
sometimes	O
used	O
in	O
this	O
setting	O
include	O
bivalirudin	other-medical
and	O
fondaparinux	other-medical
.	O

Tyrosine	other-medical
kinase	other-medical
(	O
a	O
subclass	O
of	O
protein	other-medical
kinases	other-medical
)	O
is	O
an	O
enzyme	other-medical
that	O
transfers	O
a	O
phosphate	other-medical
group	other-medical
from	O
an	O
ATP	other-medical
molecule	other-medical
to	O
a	O
protein	O
in	O
a	O
cell	O
.	O

Azerizin	other-medical
is	O
claimed	O
to	O
be	O
a	O
proprietary	O
blend	O
of	O
the	O
natural	O
ingredients	O
nicotinamide	O
,	O
azelaic	O
acid	O
,	O
quercetin	O
and	O
curcumin	O
that	O
purportedly	O
combine	O
the	O
anti-inflammatory	O
and	O
antimicrobial	O
properties	O
,	O
along	O
with	O
inhibiting	O
effects	O
on	O
sebum	O
production	O
.	O

Diethyl	O
ether	other-medical
in	O
anesthetic	O
dosage	O
is	O
an	O
inhalant	O
which	O
has	O
a	O
long	O
history	O
of	O
recreational	O
use	O
.	O

Emergency	other-medical
contraception	other-medical
was	O
being	O
developed	O
and	O
produced	O
by	O
Hoechst	O
under	O
the	O
name	O
RU-486	other-medical
.	O

Palliative	other-medical
care	other-medical
specialists	O
can	O
help	O
with	O
physical	O
symptoms	O
,	O
emotional	O
factors	O
such	O
as	O
loss	O
of	O
function	O
and	O
jobs	O
,	O
depression	O
,	O
fear	O
,	O
and	O
existential	O
concerns	O
.	O

Brand	O
names	O
of	O
MPA	other-medical
in	O
combination	O
with	O
CEEs	other-medical
as	O
oral	O
tablets	O
in	O
different	O
countries	O
include	O
Prempro	other-medical
,	O
Premphase	other-medical
,	O
Premique	other-medical
,	O
Premia	other-medical
,	O
and	O
Premelle	other-medical
.	O

The	O
ODT	other-medical
serves	O
as	O
an	O
alternative	O
dosage	O
form	O
for	O
patients	O
who	O
experience	O
dysphagia	O
(	O
difficulty	O
in	O
swallowing	O
)	O
or	O
for	O
where	O
compliance	O
is	O
a	O
known	O
issue	O
and	O
therefore	O
an	O
easier	O
dosage	O
form	O
to	O
take	O
ensures	O
that	O
medication	O
is	O
taken	O
.	O

Flatulence	other-medical
has	O
been	O
recorded	O
in	O
whales	O
.	O

Analgesics	other-medical
are	O
frequently	O
used	O
in	O
combination	O
,	O
such	O
as	O
the	O
paracetamol	other-medical
and	O
codeine	other-medical
preparations	other-medical
found	O
in	O
many	O
non-prescription	O
pain	O
relievers	O
.	O

In	O
addition	O
to	O
single-drug	O
formulations	O
,	O
MPA	other-medical
is	O
marketed	O
in	O
combination	O
with	O
the	O
estrogens	O
CEEs	other-medical
,	O
estradiol	O
,	O
and	O
estradiol	O
valerate	O
.	O

This	O
includes	O
providing	O
methadone	other-medical
for	O
addicts	O
as	O
well	O
as	O
providing	O
psychiatrists	O
,	O
nurses	O
,	O
and	O
case	O
works	O
,	O
additionally	O
the	O
program	O
``	O
also	O
provides	O
educational	O
programs	O
for	O
specific	O
patients	O
who	O
were	O
under	O
conditions	O
of	O
deferred	O
prosecution	O
.	O
''	O

Doxorubicin	other-medical
is	O
loaded	O
into	O
the	O
liposomes	O
just	O
before	O
administration	O
to	O
patients	O
with	O
a	O
maximum	O
single	O
dose	O
of	O
75	O
mg/m2	O
every	O
3	O
weeks	O
.	O

In	O
Lupus	O
Nephritis	O
,	O
a	O
common	O
manifestation	O
of	O
SLE	O
,	O
patients	O
are	O
often	O
prescribed	O
methylprednisolone	other-medical
concomitantly	O
with	O
immunosuppressants	other-medical
.	O

The	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
lomitapide	other-medical
on	O
21	O
December	O
2012	O
,	O
as	O
an	O
orphan	O
drug	O
to	O
reduce	O
LDL	O
cholesterol	O
,	O
total	O
cholesterol	O
,	O
apolipoprotein	O
B	O
,	O
and	O
non-high-density	O
lipoprotein	O
(	O
non-HDL	O
)	O
cholesterol	O
in	O
patients	O
with	O
homozygous	O
familial	O
hypercholesterolemia	O
(	O
HoFH	O
)	O
.	O

In	O
the	O
early	O
hours	O
of	O
22	O
September	O
2015	O
,	O
Gray	O
and	O
fellow	O
South	O
Sydney	O
teammate	O
and	O
best	O
friend	O
Dylan	O
Walker	O
were	O
hospitalized	O
after	O
the	O
pair	O
overdosed	O
on	O
prescription	O
drugs	O
Oxycodone	other-medical
and	O
Tramadol	other-medical
at	O
Gray	O
's	O
apartment	O
in	O
Rosebery	O
.	O

This	O
serves	O
as	O
evidence	O
for	O
the	O
idea	O
FITM2	O
is	O
functionally	O
regulated	O
by	O
PPAR	other-medical
γ	other-medical
.	O

He	O
has	O
been	O
particularly	O
critical	O
of	O
Rachel	O
Carson	O
who	O
,	O
he	O
wrote	O
,	O
``	O
misrepresented	O
the	O
existing	O
science	O
on	O
bird	O
reproduction	O
and	O
was	O
wrong	O
about	O
DDT	other-medical
causing	O
cancer	O
.	O
''	O

As	O
lorazepam	other-medical
can	O
have	O
paradoxical	O
effects	O
,	O
haloperidol	other-medical
is	O
sometimes	O
given	O
at	O
the	O
same	O
time	O
.	O

2C-T	other-medical
(	O
or	O
4-methylthio-2,5-DMPEA	other-medical
)	O
is	O
a	O
psychedelic	O
and	O
hallucinogenic	O
drug	O
of	O
the	O
2C	O
family	O
.	O

Lisinopril	other-medical
/	O
amlodipine	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Lisonorm	O
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
high	O
blood	O
pressure	O
.	O

He	O
wrote	O
seminal	O
papers	O
in	O
the	O
areas	O
of	O
hematology	other-medical
and	O
iron	other-medical
metabolism	other-medical
.	O

First	O
described	O
in	O
1913	O
,	O
little	O
was	O
known	O
about	O
the	O
cause	O
of	O
the	O
condition	O
until	O
MRI	other-medical
studies	O
were	O
performed	O
in	O
the	O
1990s	O
.	O

The	O
increased	O
iron	O
stores	O
in	O
the	O
organs	O
involved	O
,	O
especially	O
in	O
the	O
liver	O
and	O
pancreas	O
,	O
result	O
in	O
characteristic	O
findings	O
on	O
unenhanced	O
CT	other-medical
and	O
a	O
decreased	O
signal	O
intensity	O
in	O
MRI	other-medical
scans	O
.	O

Ribociclib	other-medical
,	O
an	O
inhibitor	O
of	O
CDK4	O
and	O
CDK6	O
,	O
is	O
US	O
FDA	O
approved	O
in	O
combination	O
with	O
letrozole	other-medical
for	O
treatment	O
of	O
breast	O
cancer	O
in	O
patients	O
with	O
a	O
hormone	O
receptor	O
positive	O
,	O
HER2	O
negative	O
advanced	O
metastatic	O
breast	O
cancer	O
.	O

Neurodevelopmental	O
outcome	O
of	O
prenatally	O
diagnosed	O
boys	O
with	O
47	O
,	O
XXY	O
(	O
Klinefelter	O
syndrome	O
)	O
and	O
the	O
potential	O
influence	O
of	O
early	other-medical
hormonal	other-medical
therapy	other-medical
(	O
EHT	other-medical
)	O
.	O

Bevacizumab	other-medical
can	O
also	O
be	O
combined	O
with	O
platinum	other-medical
chemotherapy	other-medical
,	O
a	O
combination	O
that	O
has	O
had	O
positive	O
preliminary	O
results	O
in	O
PFS	O
,	O
but	O
equivocal	O
results	O
regarding	O
overall	O
survival	O
.	O

A	O
goitre	other-medical
may	O
have	O
one	O
nodule	other-medical
–	O
uninodular	other-medical
,	O
multiple	O
nodules	other-medical
–	O
multinodular	other-medical
,	O
or	O
be	O
diffuse	O
.	O

If	O
use	O
of	O
amitriptyline	other-medical
is	O
warranted	O
,	O
therapeutic	O
drug	O
monitoring	O
is	O
recommended	O
to	O
guide	O
dose	O
adjustments	O
.	O

An	O
example	O
of	O
its	O
use	O
as	O
a	O
protecting	O
group	O
in	O
a	O
complex	O
organic	O
synthesis	O
is	O
the	O
Nicolaou	other-medical
Taxol	other-medical
total	O
synthesis	O
.	O

There	O
are	O
fixed-dose	O
combination	O
drugs	O
,	O
such	O
as	O
ACE	other-medical
inhibitor	other-medical
and	O
thiazide	O
combinations	O
.	O

The	O
same	O
study	O
showed	O
taking	O
potassium	other-medical
supplements	other-medical
during	O
gossypol	other-medical
treatment	O
did	O
not	O
prevent	O
hypokalemia	O
in	O
primates	O
.	O

Blizzard	O
also	O
negotiated	O
major	O
settlements	O
over	O
diet	O
drugs	O
and	O
Ephedra	other-medical
supplements	O
including	O
products	O
Fen-Phen	other-medical
and	O
Metabolife	other-medical
.	O

Multiple	O
studies	O
have	O
found	O
docusate	other-medical
to	O
be	O
no	O
more	O
effective	O
than	O
a	O
placebo	O
for	O
improving	O
constipation	O
.	O

In	O
October	O
2010	O
FDA	O
notified	O
consumers	O
that	O
``	O
Slimming	O
Beauty	O
Bitter	O
Orange	O
Slimming	O
Capsules	O
contain	O
the	O
active	O
pharmaceutical	O
ingredient	O
sibutramine	other-medical
,	O
a	O
prescription-only	O
drug	O
which	O
is	O
a	O
stimulant	O
.	O

Lubar	O
(	O
1989	O
)	O
studied	O
SMR	O
biofeedback	O
to	O
treat	O
attention	other-medical
disorders	other-medical
and	O
epilepsy	other-medical
in	O
collaboration	O
with	O
Sterman	O
.	O

Cases	O
of	O
individuals	O
being	O
sentenced	O
to	O
time	O
in	O
prison	O
and	O
other	O
penalties	O
for	O
selling	O
pure	O
dextromethorphan	other-medical
in	O
this	O
form	O
have	O
been	O
reported	O
,	O
because	O
of	O
the	O
incidental	O
violation	O
of	O
more	O
general	O
laws	O
for	O
the	O
sale	O
of	O
legitimate	O
drugs	O
–	O
such	O
as	O
resale	O
of	O
a	O
medication	O
without	O
proper	O
warning	O
labels	O
.	O

A	O
stroke	O
is	O
caused	O
by	O
hypoperfusion	O
(	O
lack	O
of	O
oxygen	O
)	O
to	O
an	O
area	O
of	O
the	O
brain	O
,	O
which	O
is	O
commonly	O
caused	O
by	O
thrombosis	other-medical
or	O
embolism	other-medical
.	O

One	O
clinical	O
trial	O
of	O
ranibizumab	other-medical
for	O
age-related	O
macular	O
degeneration	O
administered	O
intravitreally	O
reported	O
intraocular	O
inflammation	O
rates	O
between	O
1.4	O
%	O
and	O
2.9	O
%	O
.	O

Given	O
its	O
irritant	O
nature	O
to	O
mammal	O
tissues	O
,	O
capsaicin	O
is	O
widely	O
used	O
to	O
determine	O
the	O
cough	O
threshold	O
and	O
as	O
a	O
tussive	O
stimulant	O
in	O
clinical	O
research	O
of	O
cough	other-medical
suppressants	other-medical
.	O

However	O
,	O
the	O
use	O
of	O
stimulants	other-medical
in	O
the	O
fragile	O
X	O
population	O
is	O
associated	O
with	O
a	O
greater	O
frequency	O
of	O
adverse	O
events	O
including	O
increased	O
anxiety	O
,	O
irritability	O
and	O
mood	O
lability	O
.	O

Haloperidol	other-medical
is	O
also	O
used	O
on	O
many	O
different	O
kinds	O
of	O
animals	O
for	O
nonselective	O
tranquilization	O
and	O
diminishing	O
behavioral	O
arousal	O
,	O
in	O
veterinary	O
and	O
other	O
settings	O
including	O
captivity	O
management	O
.	O

Ketazolam	other-medical
breaks	O
down	O
in	O
the	O
blood	O
to	O
diazepam	other-medical
which	O
breaks	O
down	O
to	O
demoxepam	other-medical
which	O
breaks	O
down	O
to	O
desmethyldiazepam	O
.	O

His	O
reports	O
concluded	O
that	O
Penicillin	other-medical
in	O
this	O
context	O
,	O
should	O
be	O
used	O
early	O
in	O
the	O
treatment	O
of	O
infected	O
wound	O
rather	O
than	O
at	O
the	O
later	O
stage	O
of	O
chronic	O
suppuration	O
.	O

Unlike	O
aspirin	other-medical
,	O
it	O
is	O
safe	O
for	O
children	O
,	O
as	O
paracetamol	other-medical
is	O
not	O
associated	O
with	O
a	O
risk	O
of	O
Reye	O
's	O
syndrome	O
in	O
children	O
with	O
viral	O
illnesses	O
.	O

Benzodiazepine	other-medical
injectors	O
are	O
almost	O
four	O
times	O
more	O
likely	O
to	O
inject	O
using	O
a	O
shared	O
needle	O
than	O
non-	O
benzodiazepine	other-medical
-using	O
injectors	O
.	O

Traditionally	O
,	O
gonorrhea	O
was	O
diagnosed	O
with	O
Gram	other-medical
stain	other-medical
and	O
culture	O
;	O
however	O
,	O
newer	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
testing	O
methods	O
are	O
becoming	O
more	O
common	O
.	O

Plantar	O
warts	O
are	O
not	O
prevented	O
by	O
inoculation	O
with	O
HPV	other-medical
vaccines	O
because	O
the	O
warts	O
are	O
caused	O
by	O
different	O
strains	O
of	O
HPV	other-medical
.	O

Salicylic	other-medical
acid	other-medical
as	O
a	O
medication	O
is	O
used	O
most	O
commonly	O
to	O
help	O
remove	O
the	O
outer	O
layer	O
of	O
the	O
skin	O
.	O

Isavuconazonium	other-medical
comprises	O
an	O
``	O
N	O
''	O
-	O
(	O
3-acetoxypropyl	O
)	O
-	O
''	O
N	O
''	O
-methylamino-carboxymethyl	O
group	O
linked	O
through	O
an	O
ester	O
moiety	O
to	O
the	O
triazole	O
nitrogen	O
in	O
isavuconazole	O
.	O

This	O
lipodystrophy	O
is	O
colloquially	O
known	O
as	O
``	O
Crix	O
belly	O
''	O
,	O
after	O
indinavir	other-medical
(	O
Crixivan	other-medical
)	O
.	O

Proline	other-medical
racemase	O
is	O
inhibited	O
by	O
pyrrole-2-carboxylic	O
acid	O
,	O
a	O
transition	O
state	O
analogue	O
that	O
is	O
flat	O
like	O
the	O
transition	O
state	O
.	O

He	O
enjoyed	O
large	O
royalties	O
from	O
Smith	O
,	O
Kline	O
&	O
amp	O
;	O
French	O
(	O
SKF	O
)	O
because	O
he	O
sold	O
his	O
patent	O
rights	O
for	O
amphetamine	other-medical
to	O
the	O
company	O
and	O
it	O
enjoyed	O
large	O
sales	O
.	O

Treatment	O
may	O
include	O
pain	O
medications	O
,	O
NSAIDs	other-medical
,	O
and	O
elevation	O
.	O

On	O
29	O
June	O
1888	O
,	O
he	O
performed	O
the	O
first	O
appendicectomy	other-medical
in	O
England	O
.	O

This	O
is	O
likely	O
due	O
to	O
venlafaxine	other-medical
's	O
relatively	O
short	O
half-life	O
and	O
therefore	O
rapid	O
clearance	O
upon	O
discontinuation	O
.	O

Hemorrhage	other-medical
and	O
myonecrosis	other-medical
initiated	O
by	O
D.	O
acuts	O
,	O
A.	O
halys	O
,	O
N.	O
atra	O
,	O
and	O
B.	O
multicinctus	O
in	O
an	O
animal	O
model	O
were	O
significantly	O
reversed	O
by	O
varespladib	other-medical
.	O

Generally	O
speaking	O
,	O
retinoids	other-medical
increase	O
the	O
skin	O
's	O
sensitivity	O
to	O
sunlight	O
and	O
are	O
therefore	O
recommended	O
for	O
use	O
at	O
night	O
.	O

It	O
is	O
most	O
commonly	O
available	O
as	O
the	O
hydrochloride	other-medical
salt	other-medical
,	O
clenbuterol	other-medical
hydrochloride	other-medical
.	O

Cimetidine	other-medical
inhibits	O
ALA	other-medical
synthase	O
activity	O
and	O
hence	O
may	O
have	O
some	O
therapeutic	O
value	O
in	O
preventing	O
and	O
treating	O
acute	O
porphyria	O
attacks	O
.	O

Many	O
BIG	O
studies	O
have	O
been	O
practice-changing	O
,	O
for	O
example	O
,	O
putting	O
aromatase	O
inhibitors	O
on	O
the	O
map	O
(	O
BIG	O
1-98	O
)	O
,	O
changing	O
how	O
we	O
treat	O
young	O
women	O
with	O
breast	O
cancer	O
(	O
SOFT	O
)	O
,	O
leading	O
to	O
a	O
major	O
breakthrough	O
in	O
treating	O
HER2-positive	O
breast	O
cancer	O
(	O
HERA	O
)	O
,	O
or	O
helping	O
physicians	O
evaluate	O
which	O
women	O
with	O
early	O
breast	O
cancer	O
could	O
be	O
spared	O
chemotherapy	other-medical
after	O
surgery	O
(	O
MINDACT	O
)	O
.	O

Common	O
symptoms	O
,	O
which	O
tend	O
to	O
be	O
vague	other-medical
,	O
include	O
fatigue	other-medical
(	O
unrelieved	O
by	O
sleep	O
;	O
occurs	O
in	O
66	O
%	O
of	O
cases	O
)	O
,	O
lack	other-medical
of	other-medical
energy	other-medical
,	O
weight	other-medical
loss	other-medical
,	O
joint	other-medical
aches	other-medical
and	other-medical
pains	other-medical
(	O
which	O
occur	O
in	O
about	O
70	O
%	O
of	O
cases	O
)	O
,	O
arthritis	other-medical
(	O
14–38	O
%	O
of	O
cases	O
)	O
,	O
dry	other-medical
eyes	other-medical
,	O
swelling	other-medical
of	other-medical
the	other-medical
knees	other-medical
,	O
blurry	other-medical
vision	other-medical
,	O
shortness	other-medical
of	other-medical
breath	other-medical
,	O
a	O
dry	O
,	O
hacking	other-medical
cough	other-medical
,	O
or	O
skin	other-medical
lesions	other-medical
.	O

Many	O
of	O
these	O
substances	O
,	O
far	O
from	O
contributing	O
to	O
longevity	O
,	O
were	O
actively	O
toxic	O
and	O
resulted	O
in	O
Chinese	O
alchemical	O
elixir	other-medical
poisoning	O
.	O

In	O
general	O
,	O
short-term	O
therapy	O
is	O
more	O
effective	O
than	O
long-term	O
therapy	O
with	O
clonazepam	other-medical
for	O
the	O
treatment	O
of	O
epilepsy	O
.	O

Unlike	O
for	O
egg	O
allergy	O
,	O
for	O
which	O
there	O
is	O
active	O
research	O
on	O
trying	O
oral	other-medical
immunotherapy	other-medical
(	O
OIT	other-medical
)	O
to	O
desensitize	O
people	O
to	O
egg	O
allergens	O
,	O
a	O
2015	O
review	O
mentioned	O
that	O
there	O
are	O
no	O
published	O
clinical	O
trials	O
evaluating	O
oral	other-medical
immunotherapy	other-medical
for	O
fish	O
allergy	O
.	O

Montelukast	other-medical
has	O
been	O
tested	O
in	O
clinical	O
trials	O
under	O
different	O
conditions	O
to	O
observe	O
different	O
adverse	O
effects	O
.	O

Oxaliplatin	other-medical
by	O
itself	O
has	O
modest	O
activity	O
against	O
advanced	O
colorectal	O
cancer	O
.	O

Secondary	O
amine	O
TCAs	other-medical
like	O
desipramine	other-medical
and	O
nortriptyline	other-medical
have	O
a	O
lower	O
risk	O
of	O
orthostatic	O
hypotension	O
than	O
other	O
TCAs	other-medical
,	O
although	O
desipramine	O
can	O
still	O
cause	O
moderate	O
orthostatic	O
hypotension	O
.	O

In	O
clinical	O
setting	O
,	O
the	O
mutations	O
in	O
either	O
the	O
thymidine	O
kinase	O
gene	O
or	O
DNA	O
polymerase	O
gene	O
has	O
caused	O
resistance	O
to	O
aciclovir	other-medical
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
if	O
combining	O
aspirin	other-medical
with	O
any	O
``	O
natural	O
''	O
supplements	O
with	O
COX-2-inhibiting	O
properties	O
,	O
such	O
as	O
garlic	O
extracts	O
,	O
curcumin	O
,	O
bilberry	O
,	O
pine	O
bark	O
,	O
ginkgo	O
,	O
fish	O
oil	O
,	O
resveratrol	O
,	O
genistein	O
,	O
quercetin	O
,	O
resorcinol	O
,	O
and	O
others	O
.	O

In	O
four	O
clinical	O
trials	O
of	O
duloxetine	other-medical
for	O
the	O
treatment	O
of	O
MDD	O
,	O
sexual	O
dysfunction	O
occurred	O
significantly	O
more	O
frequently	O
in	O
patients	O
treated	O
with	O
duloxetine	other-medical
than	O
those	O
treated	O
with	O
placebo	other-medical
,	O
and	O
this	O
difference	O
occurred	O
only	O
in	O
men	O
.	O

Heparin	other-medical
should	O
be	O
avoided	O
because	O
it	O
can	O
lead	O
to	O
hemorrhage	O
into	O
the	O
pericardial	O
sac	O
,	O
leading	O
to	O
tamponade	O
.	O

Immunodeficiency	other-medical
is	O
a	O
state	O
of	O
reduced	O
function	O
of	O
the	O
immune	O
system	O
,	O
which	O
can	O
be	O
caused	O
by	O
medical	O
conditions	O
or	O
treatments	O
.	O

Half	O
of	O
all	O
``	O
S.	O
aureus	O
``	O
infections	O
in	O
the	O
US	O
are	O
resistant	O
to	O
penicillin	other-medical
,	O
methicillin	other-medical
,	O
tetracycline	other-medical
and	O
erythromycin	other-medical
.	O

Between	O
2000	O
and	O
2014	O
there	O
was	O
an	O
``	O
alarming	O
increase	O
in	O
heroin	other-medical
use	O
across	O
the	O
country	O
and	O
an	O
epidemic	O
of	O
drug	O
overdose	O
deaths	O
''	O
.	O

As	O
the	O
number	O
of	O
opioid	other-medical
prescriptions	O
rose	O
,	O
drug	O
cartels	O
began	O
flooding	O
the	O
US	O
with	O
heroin	O
from	O
Mexico	O
.	O

Baird	O
,	O
was	O
instrumental	O
in	O
gaining	O
approval	O
for	O
the	O
use	O
of	O
RU-486	other-medical
in	O
the	O
UK	O
as	O
an	O
emergency	O
contraceptive	O
or	O
'morning	O
after	O
pill	O
'	O
.	O

The	O
American	O
Sleep	O
Apnea	O
Association	O
(	O
ASAA	O
)	O
is	O
a	O
non-profit	O
organization	O
founded	O
in	O
1990	O
by	O
persons	O
with	O
sleep	other-medical
apnea	other-medical
,	O
health	O
care	O
providers	O
and	O
researchers	O
.	O

The	O
MHA-TP	other-medical
is	O
used	O
to	O
confirm	O
a	O
syphilis	O
infection	O
after	O
another	O
method	O
tests	O
positive	O
for	O
the	O
syphilis	O
bacteria	O
.	O

After	O
residency	O
in	O
Pediatrics	other-medical
at	O
Hokkaido	O
University	O
Hospital	O
,	O
he	O
worked	O
as	O
a	O
pediatrician	other-medical
in	O
Japan	O
for	O
several	O
years	O
.	O

Itraconazole	other-medical
is	O
given	O
with	O
the	O
steroids	other-medical
,	O
as	O
it	O
is	O
considered	O
to	O
have	O
a	O
``	O
steroid-sparing	O
''	O
effect	O
,	O
causing	O
the	O
steroids	other-medical
to	O
be	O
more	O
effective	O
,	O
allowing	O
a	O
lower	O
dose	O
.	O

Bupropion	other-medical
inhibits	O
the	O
reuptake	O
of	O
dopamine	O
through	O
the	O
human	O
dopamine	O
transporter	O
and	O
norepinephrine	O
transporter	O
;	O
the	O
inhibition	O
of	O
dopamine	O
reuptake	O
through	O
the	O
norepinephrine	O
transporter	O
is	O
most	O
pronounced	O
in	O
the	O
prefrontal	O
cortex	O
of	O
humans	O
.	O

Data	O
has	O
also	O
shown	O
that	O
the	O
heroin	other-medical
shortage	O
of	O
2001	O
has	O
also	O
changed	O
who	O
in	O
Australia	O
is	O
using	O
heroin	other-medical
,	O
with	O
a	O
decline	O
in	O
younger	O
first-time	O
heroin	other-medical
users	O
injecting	O
the	O
drug	O
,	O
which	O
is	O
consistent	O
with	O
studies	O
that	O
show	O
that	O
the	O
use	O
of	O
heroin	other-medical
amongst	O
the	O
general	O
population	O
is	O
low	O
and	O
has	O
plateaued	O
since	O
2001	O
.	O

He	O
founded	O
the	O
Paris	O
Medicine	O
Company	O
,	O
creating	O
and	O
producing	O
its	O
most	O
well-known	O
patent	O
medicine	O
products	O
,	O
Grove	other-medical
’	other-medical
s	other-medical
Tasteless	other-medical
Chill	other-medical
Tonic	other-medical
and	O
Laxative	other-medical
Bromo	other-medical
Quinine	other-medical
tablets	other-medical
.	O

As	O
such	O
,	O
it	O
was	O
characterized	O
as	O
a	O
highly	O
potent	O
antimineralocorticoid	O
with	O
far	O
fewer	O
hormonal	O
side	O
effects	O
relative	O
to	O
spironolactone	other-medical
.	O

After	O
stable	O
remission	O
was	O
induced	O
,	O
the	O
standard	O
of	O
care	O
previously	O
was	O
to	O
undergo	O
2	O
years	O
of	O
maintenance	O
chemotherapy	O
with	O
methotrexate	other-medical
,	O
mercaptopurine	other-medical
and	O
ATRA	other-medical
.	O

Because	O
of	O
the	O
limited	O
amount	O
of	O
acetylcholine	O
receptors	O
that	O
are	O
available	O
for	O
binding	O
,	O
symptomatic	O
treatment	O
consists	O
of	O
using	O
an	O
acetylcholinesterase	other-medical
inhibitor	other-medical
to	O
reduce	O
the	O
breakdown	O
of	O
acetylcholine	O
in	O
the	O
neuromuscular	O
junction	O
,	O
so	O
that	O
enough	O
acetylcholine	O
will	O
be	O
present	O
for	O
the	O
small	O
number	O
of	O
unblocked	O
receptors	O
.	O

Melatonin	other-medical
receptor	other-medical
agonists	other-medical
were	O
developed	O
with	O
the	O
melatonin	O
structure	O
as	O
a	O
model	O
.	O

Some	O
reviewers	O
recommended	O
rosiglitazone	other-medical
be	O
taken	O
off	O
the	O
market	O
,	O
but	O
an	O
FDA	O
panel	O
disagreed	O
,	O
and	O
it	O
remains	O
available	O
in	O
the	O
U.S	O
.	O
From	O
November	O
2011	O
until	O
November	O
2013	O
,	O
the	O
federal	O
government	O
did	O
not	O
allow	O
Avandia	other-medical
to	O
be	O
sold	O
without	O
a	O
prescription	O
from	O
a	O
certified	O
doctor	O
;	O
moreover	O
,	O
patients	O
were	O
required	O
to	O
be	O
informed	O
of	O
the	O
risks	O
associated	O
with	O
its	O
use	O
,	O
and	O
the	O
drug	O
had	O
to	O
be	O
purchased	O
by	O
mail	O
order	O
through	O
specified	O
pharmacies	O
.	O

While	O
chloroform	O
has	O
no	O
known	O
environmental	O
hazards	O
,	O
large	O
amounts	O
of	O
exposure	O
to	O
chloroform	O
can	O
cause	O
alterations	O
in	O
the	O
mind	O
,	O
such	O
as	O
depression	other-medical
and	O
irritability	other-medical
.	O

The	O
facility	O
,	O
located	O
in	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
,	O
produced	O
BCG	other-medical
vaccine	O
products	O
,	O
made	O
with	O
the	O
Glaxo	other-medical
1077	other-medical
strain	other-medical
,	O
such	O
as	O
a	O
tuberculosis	O
vaccine	O
ImmuCYST	other-medical
,	O
a	O
BCG	other-medical
immunotherapeutic	O
,	O
a	O
bladder	O
cancer	O
drug	O
.	O

Starting	O
with	O
linked	O
COX-2	other-medical
inhibitors	other-medical
,	O
such	O
as	O
Vioxx	other-medical
(	O
rofecoxib	other-medical
)	O
in	O
2001	O
,	O
Nissen	O
was	O
one	O
of	O
the	O
first	O
physicians	O
to	O
link	O
it	O
to	O
an	O
increased	O
risk	O
of	O
heart	O
attacks	O
and	O
strokes	O
.	O

Regarding	O
the	O
incident	O
,	O
DeLong	O
stated	O
that	O
``	O
You	O
can	O
thank	O
the	O
Tylenol	other-medical
killer	O
for	O
the	O
fact	O
that	O
it	O
now	O
takes	O
a	O
blow	O
torch	O
to	O
get	O
into	O
a	O
bottle	O
of	O
Tylenol	other-medical
.	O
''	O

More	O
than	O
three	O
hundred	O
people	O
tried	O
the	O
curry	O
before	O
Dr	O
.	O
Ian	O
Rothwell	O
became	O
the	O
first	O
person	O
to	O
finish	O
a	O
dish	O
,	O
taking	O
just	O
over	O
an	O
hour	O
,	O
including	O
10	O
minutes	O
spent	O
hallucinating	other-medical
due	O
to	O
the	O
endorphin	other-medical
rush	other-medical
.	O

Cryotherapy	other-medical
,	O
sometimes	O
known	O
as	O
cold	O
therapy	O
,	O
is	O
the	O
local	O
or	O
general	O
use	O
of	O
low	O
temperatures	O
in	O
medical	O
therapy	O
.	O

Nonsteroidal	other-medical
anti-inflammatory	other-medical
drugs	other-medical
(	O
NSAIDs	other-medical
)	O
such	O
as	O
ibuprofen	other-medical
and	O
naproxen	other-medical
are	O
effective	O
in	O
relieving	O
the	O
pain	O
of	O
primary	other-medical
dysmenorrhea	other-medical
.	O

Chemotherapy	other-medical
is	O
justified	O
for	O
cancers	O
whose	O
prognosis	O
after	O
surgery	O
is	O
poor	O
without	O
additional	O
intervention	O
.	O

CNS	other-medical
behavioral	O
changes	O
such	O
as	O
chronic	O
fatigue	O
and	O
depression	O
occur	O
in	O
patients	O
who	O
are	O
undergoing	O
irradiation	O
for	O
cancer	O
therapy	O
.	O

``	O
N.	other-medical
gonorrhoeae	other-medical
''	other-medical
is	O
usually	O
isolated	O
on	O
Thayer-Martin	O
agar	O
(	O
or	O
VPN	O
)	O
agar	O
in	O
an	O
environment	O
enriched	O
with	O
3-7	O
%	O
carbon	O
dioxide	O
.	O

A	O
short	O
trial	O
period	O
of	O
gabapentin	other-medical
therapy	O
is	O
recommended	O
,	O
to	O
determine	O
the	O
effectiveness	O
for	O
that	O
person	O
.	O

The	O
main	O
interest	O
in	O
Ro15-4513	other-medical
was	O
as	O
an	O
antidote	O
to	O
alcohol	O
.	O

Levels	O
of	O
anti-GM1	other-medical
antibodies	O
are	O
especially	O
elevated	O
in	O
patients	O
with	O
prodromal	O
diarrhea	O
.	O

One	O
review	O
found	O
that	O
antivirals	O
(	O
such	O
as	O
aciclovir	other-medical
)	O
are	O
ineffective	O
in	O
improving	O
recovery	O
from	O
Bell	O
's	O
palsy	O
beyond	O
steroids	O
alone	O
in	O
mild	O
to	O
moderate	O
disease	O
.	O

Epinephrine	other-medical
is	O
the	O
drug	O
of	O
choice	O
for	O
treating	O
anaphylaxis	O
.	O

A	O
phase	O
three	O
clinical	O
trial	O
found	O
that	O
Ribocyclib	other-medical
administered	O
in	O
combination	O
with	O
letrozole	other-medical
increased	O
the	O
likelihood	O
of	O
progression	O
free	O
survival	O
to	O
63	O
%	O
in	O
the	O
first	O
18	O
months	O
of	O
therapy	O
versus	O
42	O
%	O
for	O
letrozole	other-medical
alone	O
.	O

It	O
fully	O
substitutes	O
for	O
MBDB	other-medical
but	O
not	O
amphetamine	other-medical
in	O
trained	O
animals	O
,	O
though	O
it	O
does	O
produce	O
disruption	O
for	O
the	O
latter	O
at	O
high	O
doses	O
.	O

Dexbrompheniramine/pseudoephedrine	other-medical
(	O
trade	O
name	O
Drixoral	other-medical
)	O
is	O
a	O
combination	O
medication	O
that	O
contains	O
the	O
antihistamine	O
dexbrompheniramine	other-medical
maleate	other-medical
and	O
the	O
decongestant	O
pseudoephedrine	other-medical
sulfate	other-medical
.	O

When	O
combined	O
with	O
antidepressants	O
of	O
the	O
MAOI	other-medical
or	O
SSRI	other-medical
class	O
,	O
very	O
high	O
parenteral	O
doses	O
of	O
5-HTP	O
can	O
cause	O
acute	O
serotonin	O
syndrome	O
in	O
rats	O
.	O

After	O
treatment	O
of	O
a	O
high	O
risk	O
bleeding	O
ulcer	O
endoscopically	O
giving	O
a	O
PPI	other-medical
once	O
or	O
a	O
day	O
rather	O
than	O
as	O
an	O
infusion	O
appears	O
to	O
work	O
just	O
as	O
well	O
and	O
is	O
less	O
expensive	O
(	O
the	O
method	O
may	O
be	O
either	O
by	O
mouth	O
or	O
intravenously	O
)	O
.	O

The	O
agency	O
subsidizes	O
a	O
methadone	other-medical
maintenance	O
treatment	O
program	O
in	O
Taiwan	O
.	O

Guanfacine	other-medical
has	O
been	O
studied	O
as	O
a	O
treatment	O
for	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

KvLQT1	O
are	O
also	O
expressed	O
in	O
the	O
pancreas	O
,	O
and	O
KvLQT1	O
Long	O
QT	O
syndrome	O
patients	O
has	O
been	O
shown	O
to	O
have	O
hyperinsulinemic	O
hypoglycaemia	O
following	O
an	O
oral	other-medical
glucose	other-medical
load	O
.	O

MDMA	other-medical
tablets	O
are	O
also	O
imported	O
from	O
the	O
Netherlands	O
into	O
China	O
to	O
meet	O
the	O
demand	O
.	O

It	O
also	O
participates	O
in	O
beta-alanine	other-medical
metabolism	other-medical
and	O
pantothenate	other-medical
and	O
coa	other-medical
biosynthesis	other-medical
.	O

The	O
autoimmune	O
role	O
of	O
anti-GM1	other-medical
is	O
still	O
unclear	O
.	O

Non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
such	O
as	O
Aspirin	other-medical
or	O
Ibuprofen	other-medical
,	O
are	O
contraindicated	O
because	O
they	O
interfere	O
with	O
bone	O
healing	O
.	O

Pixantrone	other-medical
also	O
reduces	O
the	O
severity	O
of	O
experimental	O
autoimmune	O
myasthenia	O
gravis	O
in	O
Lewis	O
rats	O
,	O
and	O
in	O
vitro	O
cell	O
viability	O
experiments	O
indicated	O
that	O
Pixantrone	other-medical
significantly	O
reduces	O
amyloid	O
beta	O
(	O
A	O
beta	O
(	O
1-42	O
)	O
)	O
neurotoxicity	O
,	O
a	O
mechanism	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Though	O
it	O
has	O
affinity	O
for	O
a	O
large	O
number	O
of	O
sites	O
as	O
shown	O
above	O
,	O
at	O
clinical	O
doses	O
rotigotine	other-medical
behaves	O
mostly	O
as	O
a	O
selective	O
D1-like	O
(	O
D1	O
,	O
D5	O
)	O
and	O
D2-like	O
(	O
D2	O
,	O
D3	O
,	O
D4	O
)	O
receptor	O
agonist	O
,	O
with	O
its	O
α2B-adrenergic	O
and	O
5-HT1A	O
activity	O
also	O
possibly	O
having	O
some	O
minor	O
relevance	O
.	O

In	O
addition	O
,	O
there	O
is	O
also	O
a	O
small	O
risk	O
of	O
cross-reactivity	O
in	O
patients	O
having	O
experienced	O
angioedema	O
with	O
ACE	other-medical
inhibitor	other-medical
therapy	O
.	O